Medera

Medera, as the group's headquarters, oversees three companies: Novoheart, Xellera, and Sardocor, which respectively handle preclinical drug development, clinical trials, and therapy production, mastering the value chain for next-generation advanced therapy development. Founded and led by world pioneers and visionaries in the fields of gene therapy, cell therapy, and precision medicine, Medera boasts decades of multidisciplinary scientific and clinical expertise. Our group, composed of highly synergistic companies, offers industry-leading internal capabilities, uniquely and comprehensively covering drug discovery, GMP manufacturing and analytical testing, as well as clinical development.